CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention

NCT06283888 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

1200

Enrollment

OTHER

Sponsor class

Conditions

ACS - Acute Coronary Syndrome
CYP2C19 Polymorphism

Interventions

DRUG: CYP2C19 Genotype Guided DAPT
DRUG: Conventional DAPT

Sponsor

Zunyi Medical College